ArriVent BioPharma, Inc. (AVBP)
| Market Cap | 552.92M -35.3% |
| Revenue (ttm) | 5.00M |
| Net Income | -169.97M |
| EPS | -3.67 |
| Shares Out | 51.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 757,408 |
| Open | 11.57 |
| Previous Close | 11.56 |
| Day's Range | 10.50 - 11.87 |
| 52-Week Range | 10.51 - 35.83 |
| Beta | 1.66 |
| Analysts | Strong Buy |
| Price Target | 26.20 (+145.09%) |
| Earnings Date | Nov 9, 2026 |
About AVBP
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for AVBP stock is "Strong Buy." The 12-month stock price target is $26.2, which is an increase of 145.09% from the latest price.
News
ArriVent Biopharma price target lowered to $28 from $30 at Guggenheim
Guggenheim lowered the firm’s price target on ArriVent Biopharma (AVBP) to $28 from $30 and keeps a Buy rating on the shares after the company reported Q3 results and provided…
ArriVent Biopharma price target raised to $23 from $20 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on ArriVent Biopharma (AVBP) to $23 from $20 and keeps a Buy rating on the shares. Citi upped its probability of…
ArriVent Biopharma price target raised to $24 from $21 at Truist
Truist raised the firm’s price target on ArriVent Biopharma (AVBP) to $24 from $21 and keeps a Buy rating on the shares. The company’s Q3 update is repositioning-focused, following a…
ArriVent Biopharma reports Q3 EPS (81c), consensus ($1.06)
As of September 30, the company had cash and investments of $393.2M, which is expected to fund operations to mid-2028. “Enrollment remains on track for our global Phase 3 ALPACCA…
ArriVent BioPharma Reports Third Quarter 2026 Financial Results
Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO Dosed fir...
ArriVent BioPharma Earnings release: Q3 2026
ArriVent BioPharma released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
ArriVent BioPharma Quarterly report: Q3 2026
ArriVent BioPharma has published its Q3 2026 quarterly earnings report on November 9, 2026.
Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference
HAYWARD, Calif.--(BUSINESS WIRE)-- #biotechnology--Aarvik Therapeutics (Aarvik), an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pl...
ArriVent Biopharma price target raised to $30 from $18 at Guggenheim
Guggenheim raised the firm’s price target on ArriVent Biopharma (AVBP) to $30 from $18 and keeps a Buy rating on the shares following presentation of first Phase 1 data on…
ArriVent Biopharma price target raised to $21 from $18 at Truist
Truist analyst Supawat Thongthip raised the firm’s price target on ArriVent Biopharma (AVBP) to $21 from $18 and keeps a Buy rating on the shares. The firm views today’s 27%…
ArriVent Biopharma price target raised to $25 from $18 at Oppenheimer
Oppenheimer raised the firm’s price target on ArriVent Biopharma (AVBP) to $25 from $18 and keeps an Outperform rating on the shares.
ArriVent Biopharma announces initial Phase 1 results for ARR-217
ArriVent BioPharma (AVBP) announced initial Phase 1 results for ARR-217, a cadherin-17-targeting antibody-drug conjugate, ADC, developed in partnership with Lepu Biopharma, in patients with gastrointe...
ArriVent BioPharma Transcript: Study update
ARR-217 showed a 44.8% ORR and 93.1% DCR at 6 mg/kg in heavily pretreated metastatic CRC, with mostly low-grade toxicity and 2% Grade 3 diarrhea. Phase Ib monotherapy and combination studies continue; phase III initiation is targeted by end-2027.
ArriVent BioPharma Press release: Study update
ArriVent BioPharma issued a press release on October 26, 2026, disclosing material business information to investors.
ArriVent BioPharma Slides: Study update
ArriVent BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
ArriVent cancer data support ‘best-in-class’ potential, says Clear Street
Clear Street analyst Kaveri Pohlman says ArriVent Biopharma’s (AVBP) initial Phase 1 data for ARR-217 in late-line colorectal cancer met its bull-case scenario” and support the potential for its diffe...
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innov...
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
NEWTOWN SQUARE, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innov...
ArriVent Biopharma price target lowered to $29 from $45 at B. Riley
B. Riley lowered the firm’s price target on ArriVent Biopharma (AVBP) to $29 from $45 and keeps a Buy rating on the shares. Keymed’s CM518D1 showed a 33.3% overall response…
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
NEWTOWN SQUARE, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innov...
ArriVent Biopharma doses first patient in ARR-002 trial
ArriVent BioPharma (AVBP) announced that it dosed its first patient in the Phase 1 trial in the U.S. with ARR-002, a MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate, or ADC, for ovarian…
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innov...
ArriVent Biopharma price target lowered to $27 from $47 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns lowered the firm’s price target on ArriVent Biopharma (AVBP) to $27 from $47 and keeps a Buy rating on the shares following the FURVENT trial…
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $AVBP--AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law.
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
AVBP was down 56.7% before the opening bell and traded as low as $12.09 after ArriVent disclosed that its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. An investigation into pote...